Device Trial Radar · NCT04908124
A Clinical Investigation Into the Effectiveness and Safety of Five Water Based Personal Lubricants.
Last checked: Nov 19, 2026Latest source record: Jul 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
183
Actual
Start
Mar 1, 2021
Primary completion
Jun 29, 2021
Study completion Jun 29, 2021
Sponsor
- Lead sponsor
- Reckitt Benckiser Healthcare (UK) LimitedNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- proDERM GmbH
- First posted
- Jun 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated device
- No
- Who can join
- Female only, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This clinical investigation will look at the safety of five water based personal lubricants, and teir effectiveness the relief of intimate discomfort associated with vaginal dryness.
Conditions
- Dyspareunia
- Vaginal Dryness
Interventions
Lubricant ADevice
Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
Lubricant BDevice
Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
Lubricant CDevice
Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
Lubricant DDevice
Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
Lubricant EDevice
Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Female Sexual Function Index (FSFI) score compared to baselineTime frame: 4 weeks after baseline
Locations
1 site in 1 country. Site status is shown where the registry gives one.
proDERM GmbH
Hamburg, Pinneberg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.